Format

Send to

Choose Destination
Br J Cancer. 2004 Mar;90 Suppl 1:S2-6.

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Author information

1
Department of Medicine, Baylor College of Medicine, Houston, TX, USA. kosborne@bcm.tmc.edu

Abstract

Due to their favourable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer. However, the oestrogen agonist effects of the available selective oestrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms. Fulvestrant ('Faslodex') is the first of a new type of endocrine treatment--an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. This article provides an overview of the current understanding of ER signalling and illustrates the unique mode of action of fulvestrant. Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist.

PMID:
15094757
PMCID:
PMC2750773
DOI:
10.1038/sj.bjc.6601629
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center